Stock GRTS GRITSTONE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.8134 USD +6.40% Intraday chart for Gritstone bio, Inc. +10.43% -60.13%
Apr. 15 Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform CI
Apr. 02 Top Midday Decliners MT

Evolution of the average Target Price on Gritstone bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f6ecd0978071b0e9f42f9f21ddeb183.ftV5cuCUpFHclxipDggsI7BAZ68nj6P38aUU56qHQ3k.JL8aJNP1_SOO4ymdT1p6fPcLDJZjwvqiuu1dkM-0AhMVnjccrNmVZrDtSQ~ecd64568408dbd523645816553eab0a4

Analyst Recommendations on Gritstone bio, Inc.

B. Riley Adjusts Gritstone bio's Price Target to $6 From $8, Keeps Buy Rating MT
Piper Sandler Lifts Price Target on Gritstone bio to $7 From $6, Keeps Overweight Rating MT
B. Riley Initiates Coverage of Gritstone bio With Buy Rating, Price Target of $8 Per Share MT
HC Wainwright Adjusts Gritstone bio's Price Target to $7 From $12, Keeps Buy Rating MT
Piper Sandler Starts Gritstone bio at Overweight With $6 Price Target MT
Goldman Sachs Downgrades Gritstone bio to Sell From Neutral; Price Target is $2 MT
HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating MT
HC Wainwright Adjusts Gritstone Bio's Price Target to $15 From $24, Maintains Buy Rating MT
GRITSTONE ONCOLOGY : BTIG Research Adjusts Gritstone Oncology PT to $35 From $17, Maintains Buy Rating MT
GRITSTONE ONCOLOGY : HC Wainwright Adjusts Gritstone Oncology's Price Target to $24 from $16, Keeps Buy Rating MT
GRITSTONE ONCOLOGY : Baird Downgrades Gritstone Oncology to Underperform From Outperform; Price Target is $8 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.8134 USD
Average target price
5.167 USD
Spread / Average Target
+535.19%
High Price Target
10 USD
Spread / Highest target
+1,129.41%
Low Price Target
3 USD
Spread / Lowest Target
+268.82%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gritstone bio, Inc.

B. Riley
Piper Sandler
HC Wainwright
Goldman Sachs
BTIG
Baird

Ratings for Gritstone bio, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GRTS Stock
  4. Consensus Gritstone bio, Inc.